Tag: GlobeNewswire

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

• CNSide^® CSF Molecular Profile – Solid Tumor (DNA & RNA)
• CNSide^® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA)

CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy¹. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality. 

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. 

Ordering Information

Beginning October 12, 2026, health care professionals may order CNSide CSF Molecular Profile tests through CNSide Diagnostics. The tests may be ordered independently or, when appropriate, alongside CNSide CSF Tumor Cell Enumeration. Coverage and reimbursement vary by payer and patient benefit design.

CNSide CSF Tumor Cell Enumeration is a laboratory developed test performed by CNSide Diagnostics, LLC in its CLIA-certified, CAP-accredited laboratory in Houston, Texas. CNSide CSF Molecular Profile tests are laboratory developed tests currently performed for CNSide Diagnostics by Genomic Testing Cooperative, LCA, a CLIA-certified and CAP-accredited reference laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration and are available through CNSide Diagnostics to health care professionals in the U.S.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid-based diagnostic tests for cancers involving the central nervous system. The CNSide^® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies.

Current offerings include CNSide^® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and CNSide^® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS. For more information, visit www.cnside-dx.com.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof.

Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements regarding the timing of availability of CNSide CSF Molecular Profile tests; its expected turnaround time, performance and clinical utility; physician adoption and ordering patterns; the timing and content of additional CNSide menu tests; coverage, billing and reimbursement for CNSide CSF Molecular Profile and other CNSide tests; the Company’s reliance on third-party laboratory service providers; the potential market for CNSide tests; the timing in which CNSide tests are commercially launched and commercialization is expanded; the development and utility of CNSide tests; and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Actual results may differ materially due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

¹ Albitar M, Charifa A, Agersborg S, et al. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors. The Journal of Liquid Biopsy. 2026;14:100500.

Investor Contact
CORE IR
IR@cerenome.com

OREM, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, today announced it broke ground on a solar power system for a new AI data center located in Reno, Nevada.

John Paul Bergh, EVP of Cobalt Power Systems and SunPower New Homes, said, “While not yet at the 100-megawatt-plus scale, this solar project is complex, and its installation is a learning opportunity for us. As such, SunPower is honored to have been awarded the first phase of the Reno AI data center project, reflecting our target of expanding our commercial system capability when rigorous performance specs are required.”

T.J. Rodgers, CEO of SunPower, said, “Our ASP for a residential solar job is about $32 thousand, but our high-tech Silicon Valley installations average $44 thousand with some commercial installations running well over $1 million. Bigger is better on the bottom line.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:
Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower

OREM, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, today announced it broke ground on a solar power system for a new AI data center located in Reno, Nevada.

John Paul Bergh, EVP of Cobalt Power Systems and SunPower New Homes, said, “While not yet at the 100-megawatt-plus scale, this solar project is complex, and its installation is a learning opportunity for us. As such, SunPower is honored to have been awarded the first phase of the Reno AI data center project, reflecting our target of expanding our commercial system capability when rigorous performance specs are required.”

T.J. Rodgers, CEO of SunPower, said, “Our ASP for a residential solar job is about $32 thousand, but our high-tech Silicon Valley installations average $44 thousand with some commercial installations running well over $1 million. Bigger is better on the bottom line.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:
Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower

OREM, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, today announced it broke ground on a solar power system for a new AI data center located in Reno, Nevada.

John Paul Bergh, EVP of Cobalt Power Systems and SunPower New Homes, said, “While not yet at the 100-megawatt-plus scale, this solar project is complex, and its installation is a learning opportunity for us. As such, SunPower is honored to have been awarded the first phase of the Reno AI data center project, reflecting our target of expanding our commercial system capability when rigorous performance specs are required.”

T.J. Rodgers, CEO of SunPower, said, “Our ASP for a residential solar job is about $32 thousand, but our high-tech Silicon Valley installations average $44 thousand with some commercial installations running well over $1 million. Bigger is better on the bottom line.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:
Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower

– Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia

– If approved, oral infigratinib would be the first and only approved oral therapy and a potential best-in-class treatment option for children with achondroplasia

– PROPEL 3 met its primary endpoint and key secondary endpoints, delivering the strongest efficacy package reported to date in achondroplasia: the largest AHV treatment effect of any Phase 3 study (+2.10 cm/yr; p<0.0001), and the first and only statistically significant improvement in both body proportionality and arm span in an achondroplasia Phase 3 trial (Proportionality: mean difference of -0.05 in ages 3–8, p<0.05; arm span z-score: +0.37 SD, p<0.0001)

-Treatment with oral infigratinib for 52 weeks in PROPEL 3 also resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

– BridgeBio anticipates U.S. launch of oral infigratinib upon approval

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 4, 2027, and BridgeBio is prepared to launch oral infigratinib upon approval.

“Being granted Priority Review means we are one step closer to potential FDA approval of the first oral treatment option for children with achondroplasia,” said Justin To, Chief Executive Officer of BridgeBio Skeletal Dysplasias. “We also understand that for many families, it’s about more than just height or having an oral option. To that end, we are excited by the data we have generated on arm span, sleep apnea, ear infections, and proportionality, and we remain committed to further evaluate and share the impact of oral infigratinib on measures beyond growth. We are grateful to the families and investigators who have partnered with us, and we are moving with urgency alongside the FDA.”

PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children with achondroplasia, met its primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (LS mean treatment difference of +1.74 cm/year; mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change from baseline in height Z-score (p<0.0001). In a pre-specified exploratory analysis in children younger than 8 years (more than half of participants), oral infigratinib became the first therapeutic option to show a statistically significant improvement in body proportionality against placebo in a randomized achondroplasia trial. Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. These data were published as an original research article in The New England Journal of Medicine and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here. Additionally, BridgeBio also shared emerging data for oral infigratinib at ESPE about improvements beyond height for people with achondroplasia, including stabilizing sleep apnea measures, reducing rate of ear infections, and impacting body composition. The results can be found here.

“For children and families living with achondroplasia, today’s news represents meaningful progress toward potentially expanding the range of available options,” said Michael Hughes, Chair of the Biotech Industry Liaison Committee at Little People of America. “Our community holds diverse priorities and perspectives, and what matters is that individuals and families have meaningful choices as they consider their own healthcare goals. This milestone brings us one step closer to potentially having another option for families to consider together with their healthcare providers. We appreciate BridgeBio’s continued engagement with the achondroplasia community and its efforts to incorporate community perspectives throughout the development process.”

BridgeBio intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026.

Oral infigratinib has received Breakthrough Therapy Designation from the FDA based on results from the PROPEL 2 clinical trial, which met the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. Oral infigratinib is the only therapeutic option in development for achondroplasia to hold Breakthrough Therapy Designation. In addition, oral infigratinib has received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA, as well as Orphan Drug Designation from the EMA.

Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families.

About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3. Oral infigratinib has received Breakthrough Therapy Designation, Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the U.S. FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including the timing and likelihood of potential FDA approval and BridgeBio’s anticipated U.S. launch upon approval; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the fourth quarter of 2026; BridgeBio’s plans to further evaluate and share the potential impact of oral infigratinib on measures beyond growth; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions.

Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, including by the FDA’s February 4, 2027 PDUFA target action date, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. upon approval or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission in the fourth quarter of 2026, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; and that BridgeBio’s plans to further evaluate, share, study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

– Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia

– If approved, oral infigratinib would be the first and only approved oral therapy and a potential best-in-class treatment option for children with achondroplasia

– PROPEL 3 met its primary endpoint and key secondary endpoints, delivering the strongest efficacy package reported to date in achondroplasia: the largest AHV treatment effect of any Phase 3 study (+2.10 cm/yr; p<0.0001), and the first and only statistically significant improvement in both body proportionality and arm span in an achondroplasia Phase 3 trial (Proportionality: mean difference of -0.05 in ages 3–8, p<0.05; arm span z-score: +0.37 SD, p<0.0001)

-Treatment with oral infigratinib for 52 weeks in PROPEL 3 also resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

– BridgeBio anticipates U.S. launch of oral infigratinib upon approval

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 4, 2027, and BridgeBio is prepared to launch oral infigratinib upon approval.

“Being granted Priority Review means we are one step closer to potential FDA approval of the first oral treatment option for children with achondroplasia,” said Justin To, Chief Executive Officer of BridgeBio Skeletal Dysplasias. “We also understand that for many families, it’s about more than just height or having an oral option. To that end, we are excited by the data we have generated on arm span, sleep apnea, ear infections, and proportionality, and we remain committed to further evaluate and share the impact of oral infigratinib on measures beyond growth. We are grateful to the families and investigators who have partnered with us, and we are moving with urgency alongside the FDA.”

PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children with achondroplasia, met its primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (LS mean treatment difference of +1.74 cm/year; mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change from baseline in height Z-score (p<0.0001). In a pre-specified exploratory analysis in children younger than 8 years (more than half of participants), oral infigratinib became the first therapeutic option to show a statistically significant improvement in body proportionality against placebo in a randomized achondroplasia trial. Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. These data were published as an original research article in The New England Journal of Medicine and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here. Additionally, BridgeBio also shared emerging data for oral infigratinib at ESPE about improvements beyond height for people with achondroplasia, including stabilizing sleep apnea measures, reducing rate of ear infections, and impacting body composition. The results can be found here.

“For children and families living with achondroplasia, today’s news represents meaningful progress toward potentially expanding the range of available options,” said Michael Hughes, Chair of the Biotech Industry Liaison Committee at Little People of America. “Our community holds diverse priorities and perspectives, and what matters is that individuals and families have meaningful choices as they consider their own healthcare goals. This milestone brings us one step closer to potentially having another option for families to consider together with their healthcare providers. We appreciate BridgeBio’s continued engagement with the achondroplasia community and its efforts to incorporate community perspectives throughout the development process.”

BridgeBio intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026.

Oral infigratinib has received Breakthrough Therapy Designation from the FDA based on results from the PROPEL 2 clinical trial, which met the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. Oral infigratinib is the only therapeutic option in development for achondroplasia to hold Breakthrough Therapy Designation. In addition, oral infigratinib has received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA, as well as Orphan Drug Designation from the EMA.

Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families.

About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3. Oral infigratinib has received Breakthrough Therapy Designation, Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the U.S. FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including the timing and likelihood of potential FDA approval and BridgeBio’s anticipated U.S. launch upon approval; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the fourth quarter of 2026; BridgeBio’s plans to further evaluate and share the potential impact of oral infigratinib on measures beyond growth; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions.

Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, including by the FDA’s February 4, 2027 PDUFA target action date, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. upon approval or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission in the fourth quarter of 2026, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; and that BridgeBio’s plans to further evaluate, share, study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

– Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia

– If approved, oral infigratinib would be the first and only approved oral therapy and a potential best-in-class treatment option for children with achondroplasia

– PROPEL 3 met its primary endpoint and key secondary endpoints, delivering the strongest efficacy package reported to date in achondroplasia: the largest AHV treatment effect of any Phase 3 study (+2.10 cm/yr; p<0.0001), and the first and only statistically significant improvement in both body proportionality and arm span in an achondroplasia Phase 3 trial (Proportionality: mean difference of -0.05 in ages 3–8, p<0.05; arm span z-score: +0.37 SD, p<0.0001)

-Treatment with oral infigratinib for 52 weeks in PROPEL 3 also resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

– BridgeBio anticipates U.S. launch of oral infigratinib upon approval

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 4, 2027, and BridgeBio is prepared to launch oral infigratinib upon approval.

“Being granted Priority Review means we are one step closer to potential FDA approval of the first oral treatment option for children with achondroplasia,” said Justin To, Chief Executive Officer of BridgeBio Skeletal Dysplasias. “We also understand that for many families, it’s about more than just height or having an oral option. To that end, we are excited by the data we have generated on arm span, sleep apnea, ear infections, and proportionality, and we remain committed to further evaluate and share the impact of oral infigratinib on measures beyond growth. We are grateful to the families and investigators who have partnered with us, and we are moving with urgency alongside the FDA.”

PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children with achondroplasia, met its primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (LS mean treatment difference of +1.74 cm/year; mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change from baseline in height Z-score (p<0.0001). In a pre-specified exploratory analysis in children younger than 8 years (more than half of participants), oral infigratinib became the first therapeutic option to show a statistically significant improvement in body proportionality against placebo in a randomized achondroplasia trial. Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. These data were published as an original research article in The New England Journal of Medicine and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here. Additionally, BridgeBio also shared emerging data for oral infigratinib at ESPE about improvements beyond height for people with achondroplasia, including stabilizing sleep apnea measures, reducing rate of ear infections, and impacting body composition. The results can be found here.

“For children and families living with achondroplasia, today’s news represents meaningful progress toward potentially expanding the range of available options,” said Michael Hughes, Chair of the Biotech Industry Liaison Committee at Little People of America. “Our community holds diverse priorities and perspectives, and what matters is that individuals and families have meaningful choices as they consider their own healthcare goals. This milestone brings us one step closer to potentially having another option for families to consider together with their healthcare providers. We appreciate BridgeBio’s continued engagement with the achondroplasia community and its efforts to incorporate community perspectives throughout the development process.”

BridgeBio intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026.

Oral infigratinib has received Breakthrough Therapy Designation from the FDA based on results from the PROPEL 2 clinical trial, which met the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. Oral infigratinib is the only therapeutic option in development for achondroplasia to hold Breakthrough Therapy Designation. In addition, oral infigratinib has received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA, as well as Orphan Drug Designation from the EMA.

Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families.

About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3. Oral infigratinib has received Breakthrough Therapy Designation, Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the U.S. FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including the timing and likelihood of potential FDA approval and BridgeBio’s anticipated U.S. launch upon approval; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the fourth quarter of 2026; BridgeBio’s plans to further evaluate and share the potential impact of oral infigratinib on measures beyond growth; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions.

Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, including by the FDA’s February 4, 2027 PDUFA target action date, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. upon approval or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission in the fourth quarter of 2026, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; and that BridgeBio’s plans to further evaluate, share, study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

 And 6.45 m of 667 g/t Silver, Including 3.19 m of 1,339 g/t Silver In Hole 412

And 9.00 m of 222 g/t Silver, Including 0.50 m of 1,605 g/t Silver In Hole 442

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to report silver results from 28 holes at its wholly owned Langis Silver Project, located in the historic silver mining camp of Cobalt, Ontario, Canada. These results come from several different areas of the project that the Company is actively exploring. So far in 2026, the Company has completed 39,937.55 m across 182 drill holes. The Company has added a third drill rig to the Langis program, targeting 9,000 metres per month. This accelerated drilling rate is needed to meet our near-term objective of establishing a maiden Mineral Resource Estimate (“MRE”) at Langis.

Highlights

• In the Shaft 6 South East Area (S6-SE), hole LM-26-449 returned 23.50 m of 348 g/t silver from 203.00 m
  • Including 4.00 m of 1,975 g/t silver from 215.00 m
    • And including 2.00 m of 3,386 g/t silver from 215.50 m as native silver
• In the Shaft 6 West Area (S6-W), hole LM-26-412 returned 6.45 m of 667 g/t silver from 124.65 m
  • Including 3.19 m of 1,339 g/t silver from 127.31 m, and 1.00 m of 3,570 g/t silver from 128.40 m
• In the Shaft 6 East Area (S6-E), hole LM-26-433 returned 10.50 m of 85.7 g/t silver from 192.50 m
  • Including 2.35 m of 347 g/t silver from 196.25 m
• In the Shaft 6 Area (S6), hole LM-26-442 returned 9.00 m of 222 g/t silver from 119.00 m
  • Including 0.50 m of 1,605 g/t silver from 124.35 m, and 1.20 m of 666 g/t silver from 126.80 m

Chairman and CEO, Gary R. Thompson, stated, “Drilling at Langis continues to shine, delivering more multi-kilogram silver intercepts. Our high-density drilling strategy is showing results. These holes come from several different areas of the project as we are actively looking to expand known mineralization across the project.”

Figure 1. Langis Silver Project location map of drilling area and mineral claims.

Figure 2. Photograph of hole LM-26-449 at 215.73-216.00 m depth showing disseminated native silver and native silver veinlets.

Figure 3. Photograph of hole LM-26-449 at 215.73-216.00 m depth and LM-26-412 at 129.10 m depth showing native silver veins-veinlets and disseminated native silver.

Discussion

Shaft 6 South East (S6-SE)

New results from this recently discovered brownfield area (Table 1), with no mining works (see news release dated July 21, 2026), show mineralization extending to the south. Drilling to test the extension of this zone returned strong results in holes LM-26-421, LM-26-427 and LM-26-449, with hole LM-26-449 returning the main intercept of 23.50 m of 348.11 g/t silver from 203.00 m depth.

As observed in Figures 2 and 3, disseminated native silver accompanies the vein-hosted mineralization and native silver veinlets. Brixton interprets this as an upside to the traditional vein-focused exploration approach at Langis, as the disseminated silver appears to create broad shoulders of mineralization flanking the veins, which could significantly widen the mineralized envelopes.

Table 1. Selected assay intervals from drill holes in the Shaft 6 South East (S6-SE) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-419	140.00	142.00	2.00	54.80
LM-26-421	135.70	144.00	8.30	137.45
including	137.05	140.00	2.95	343.14
	150.45	150.95	0.50	140.00
	155.00	156.00	1.00	100.00
LM-26-427	179.00	185.00	6.00	95.55
including	182.00	182.50	0.50	987.00
LM-26-449	203.00	226.50	23.50	348.11
including	206.15	206.65	0.50	67.60
including	212.00	213.00	1.00	129.60
including	215.00	219.00	4.00	1,974.88
and including	215.50	217.50	2.00	3,386.25

No significant intercepts were returned from hole LM-26-425.
Note for all assay tables: All assay values are weighted averages. Reported intervals are drilling lengths, and the true widths of the mineralized intervals have not yet been determined. Reported intervals are length-weighted composites calculated at a 5 g/t Ag cut-off over contiguous samples, with limited internal dilution. A hole is reported as a significant intercept only where it contains a sub-interval exceeding 50 g/t Ag; otherwise, it is reported as no significant intercepts. Higher-grade “including” intervals reflect geological interpretation.

Shaft 6 East (S6-E)

Drilling in the Shaft 6 East (S6-E) area (Table 2) tested mineralization in this zone, with good results in holes LM-26-429 and LM-26-433; the latter returned 10.50 m of 85.74 g/t silver from 192.50 m depth. However, the Company has not yet established significant continuity of mineralization. While the mineralized intercepts warrant further exploration, the mineralization in S6-E is being intersected at greater depths, and the Company has therefore decided to move to shallower zones.

Table 2. Selected assay intervals from drill holes in the Shaft 6 East (S6-E) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-429	181.65	188.00	6.35	95.35
including	186.00	188.00	2.00	289.00
LM-26-431	227.70	228.25	0.55	240.00
LM-26-433	192.50	203.00	10.50	85.74
including	196.25	198.60	2.35	346.69
LM-26-441	210.00	217.20	7.20	11.55
including	214.50	215.00	0.50	61.40
	221.00	228.75	7.75	10.80
including	228.25	228.75	0.50	88.50
LM-26-443	206.50	207.50	1.00	43.75
including	207.00	207.50	0.50	77.70

No significant intercepts were returned from holes LM-26-437, LM-26-439 and LM-26-445.

Shaft 6 (S6)

In the Shaft 6 (S6) area (Table 3), drilling also continues to return good results around historic stopes, including holes LM-26-426, LM-26-428 and LM-26-442, with hole LM-26-442 returning the main intercept of 9.00 m of 221.91 g/t silver from 119.00 m depth.

Table 3. Selected assay intervals from drill holes in the Shaft 6 (S6) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-426	124.50	131.50	7.00	208.39
including	129.50	130.50	1.00	1,345.00
and including	130.00	130.50	0.50	2,200.00
LM-26-428	127.00	131.00	4.00	259.49
including	128.00	130.00	2.00	507.95
and including	129.00	129.50	0.50	1,090.00
	134.75	136.00	1.25	59.10
LM-26-435	132.00	137.00	5.00	41.91
including	132.00	133.00	1.00	102.00
LM-26-442	119.00	128.00	9.00	221.91
including	120.50	122.85	2.35	129.20
including	124.35	124.85	0.50	1,605.00
including	126.80	128.00	1.20	665.83
and including	126.80	127.50	0.70	1,055.00

No significant intercepts were returned from holes LM-26-430, LM-26-436, LM-26-438, LM-26-440, LM-26-444 and LM-26-446.

Shaft 6 West (S6-W)

Drilling in the Shaft 6 West (S6-W) area (Table 4) continues to confirm the good initial results reported in the news release dated September 2, 2026, with mineralization around the historic mine workings. Good results were returned in holes LM-26-412, LM-26-417, LM-26-420A and LM-26-424, with hole LM-26-412 returning the main intercept of 6.45 m of 666.95 g/t silver from 124.65 m depth.

Brixton is looking to potentially expand this mineralization at S6-W to demonstrate continuity, as the Company has been doing in the Shaft 6 South East (S6-SE) area.

Table 4. Selected assay intervals from drill holes in the Shaft 6 West (S6-W) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-412	124.65	131.10	6.45	666.95
including	127.31	130.50	3.19	1,339.39
and including	128.40	129.40	1.00	3,570.00
	135.10	145.42	10.32	102.64
including	137.50	138.00	0.50	584.00
including	141.50	143.00	1.50	441.67
LM-26-417	107.00	119.98	12.98	20.52
including	107.00	108.00	1.00	76.00
including	108.50	109.00	0.50	70.10
	122.00	129.21	7.21	137.53
including	122.00	123.00	1.00	427.00
including	126.00	128.21	2.21	239.60
	136.00	144.00	8.00	117.80
including	141.50	142.00	0.50	1,750.00
LM-26-420A	103.00	114.00	11.00	77.93
including	108.50	109.50	1.00	588.00
including	111.50	114.00	2.50	64.38
LM-26-424	121.50	136.25	14.75	46.48
including	123.50	125.00	1.50	368.33

No significant intercepts were returned from hole LM-26-422.

Figure 4. Plan Map of Langis showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to surface.

Shaded areas show where individual drill core samples from previous drilling returned ≥30 g/t Ag, projected to surface (Figures 4 & 6) or onto the section plane (Figure 5). They are a visual aid only. They are not a geological model, a mineral resource or a mineral reserve, and they do not imply continuity of mineralization between drill holes.

Figure 5. Long section A to A’ looking north (trace as in Figure 4), showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to the long-section plane.

Drill holes between 5,270,680 m N and 5,270,910 m N are projected onto a vertical west–east plane along 5,270,795 m N. Only the holes in this release are labelled and drawn with their lithology: Huronian conglomerate, Keewatin mafic volcanics and Nipissing diabase. Composites are plotted at the interval mid-point and coloured by silver grade. Shaded areas show samples ≥30 g/t Ag from previous drilling within the same window. No vertical exaggeration. Projection: points up to 115 m from the section line appear together, so intercepts that look close on the section may be separated in three dimensions. Composites and shading: same definitions and limitations as Figure 4. Reported intercepts are core lengths; true widths are not yet known.

Figure 6. Map showing drill results from the Langis Shaft 6 area, highlights from the 2026 campaign to date.

Table 5. Drill hole collar information for reported holes.

Hole ID	Pad ID	Easting (m)	Northing (m)	Elevation (m)	Azimuth	Dip	Depth (m)	Zone
LM-26-412	LM-2026-039	607210	5270820	212.0	300	-60	195.00	S6-W
LM-26-417	LM-2026-092	607230	5270820	212.9	305	-55	210.00	S6-W
LM-26-419	LM-2026-072	607550	5270728	216.9	85	-60	300.00	S6-SE
LM-26-420A	LM-2026-092	607230	5270820	212.9	295	-55	189.00	S6-W
LM-26-421	LM-2026-087	607451	5270726	217.0	90	-55	258.00	S6-SE
LM-26-422	LM-2026-093	607210	5270840	212.7	305	-50	189.00	S6-W
LM-26-424	LM-2026-093	607210	5270840	212.7	300	-55	186.00	S6-W
LM-26-425	LM-2026-085	607429	5270760	217.0	90	-55	288.00	S6-SE
LM-26-426	LM-2026-101	607401	5270805	216.6	355	-62	198.00	S6
LM-26-427	LM-2026-085	607429	5270760	217.0	90	-48	300.00	S6-SE
LM-26-428	LM-2026-101	607401	5270805	216.6	3	-63	195.00	S6
LM-26-429	LM-2026-097	607624	5270839	220.8	85	-70	249.00	S6-E
LM-26-430	LM-2026-102	607433	5270886	218.8	230	-72	177.00	S6
LM-26-431	LM-2026-097	607624	5270839	220.8	90	-65	252.00	S6-E
LM-26-433	LM-2026-096	607618	5270819	219.9	85	-70	276.00	S6-E
LM-26-435	LM-2026-102	607433	5270886	218.8	230	-59	180.00	S6
LM-26-436	LM-2026-102	607433	5270886	218.8	230	-55	210.00	S6
LM-26-437	LM-2026-096	607618	5270819	219.9	85	-65	276.00	S6-E
LM-26-438	LM-2026-103	607432	5270895	218.8	230	-66	84.00	S6
LM-26-439	LM-2026-098	607631	5270796	219.9	85	-70	300.00	S6-E
LM-26-440	LM-2026-103	607432	5270895	218.8	230	-70	121.50	S6
LM-26-441	LM-2026-099	607638	5270772	219.5	85	-70	300.00	S6-E
LM-26-442	LM-2026-103	607432	5270895	218.8	215	-73	177.00	S6
LM-26-443	LM-2026-096A	607613	5270809	220.0	85	-65	303.00	S6-E
LM-26-444	LM-2026-103	607432	5270895	218.8	230	-65	177.00	S6
LM-26-445	LM-2026-096A	607613	5270809	220.0	85	-70	298.00	S6-E
LM-26-446	LM-2026-103	607432	5270895	218.8	230	-59	192.00	S6
LM-26-449	LM-2026-094	607559	5270725	216.9	96	-58	276.00	S6-SE

About the Langis Project

An Exploration Target of 1.0 to 2.0 million tonnes grading 400 to 800 g/t silver has been conceptualized for the project. Note: The potential quantity and grade of the Exploration Target are conceptual. Insufficient exploration has been completed to define a mineral resource, and there is no certainty that further exploration will result in the target being delineated as a mineral resource.

The wholly owned Langis Silver Project, located approximately 500 km north of Toronto, Ontario, Canada, includes a former producing mine and benefits from excellent infrastructure, including all-season road access, power, rail connections, and a refiner. Silver mineralization occurs as native silver and in steeply to moderately dipping veins, veinlets, disseminations, rosettes, and fracture infill, often associated with minerals such as calcite, hematite, pyrite, cobaltite, chalcopyrite, niccolite, and gold. Mineralization is hosted across three principal rock types: Archean Keewatin volcanic and metasedimentary rocks, Proterozoic Coleman Member sedimentary rocks of the Huronian Supergroup, and Proterozoic Nipissing diabase. The geological deposit model for the area is a continental-rift extensional depositional environment. The Langis Mine produced 10.4 million ounces of silver intermittently between 1908 and 1989 at a head grade of 20 to 25 opt, with reported recoveries of 88% to 98%. Previous operators developed over 10 km of underground workings; however, shafts and openings have been capped and sealed. Historically, reported silver mines in the Cobalt Camp have collectively produced over 445 million ounces of silver. We also understand, through personal communication with mine workers in the camp, that ultra-high-grade native silver collector pieces did not make it through the mills, suggesting that the camp’s actual silver production is significantly higher than the reported numbers. The historic production figures referenced above are sourced from third-party records and personal communications, have not been verified by Brixton or by the Qualified Person, and should not be relied upon.

Quality Assurance & Quality Control

Quality assurance and quality control protocols for drill core sampling were developed by Brixton. Core samples were mostly taken at 2.0 m intervals. High-grade intervals were taken at 0.50 m to 1.00 m intervals. Blanks, duplicates (lab pulp), and certified reference materials were inserted at a combined rate of up to 15%. Core samples were cut in half, bagged, zip-tied, and sent directly to the ALS Minerals preparation facility in Sudbury, Ontario. ALS Minerals Laboratories is registered to ISO 9001:2015 and ISO 17025 accreditations for laboratory procedures. Samples were analyzed at ALS Laboratory Facilities in North Vancouver, British Columbia, for gold by fire assay with an atomic absorption finish. Ag, Pb, Cu, and Zn, as well as 48 additional elements, were analyzed using a four-acid digestion with an ICP-MS finish. Overlimit silver samples were analyzed using fire assay and gravimetric finish, and/or fire assay and gravimetric finish on concentrates. The certified reference materials were acquired from CDN Resource Laboratories Ltd. of Langley, British Columbia, and the standards inserted varied with the type and abundance of mineralization observed in the primary sample. Blank material used consisted of non-mineralized siliceous landscaping rock. A copy of the QAQC protocols is available on the Company’s website.

Corporate Update

On October 1, 2026, Eldorado Gold Corporation gave notice of termination to Brixton for its Earn-in Agreement for the Atlin Goldfields Project. The Atlin Goldfields Project is an exploration stage project with orogenic and intrusion related gold deposit type characteristics. Brixton holds the project 100% free and clear with low to no NSR’s. The Company intends to seek a farmout or sale of the Project. Several high-grade gold showings have seen limited work.

Qualified Person (QP)

Mr. Gary Thompson, P.Geo., is the Chairman and CEO and a senior geologist for the Company who is a Qualified Person as defined by National Instrument 43-101. Mr. Thompson has verified the referenced data and analytical results disclosed in this press release and has approved the technical information presented herein.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on advancing its mining projects. Brixton wholly owns five exploration projects: the Thorn copper-gold-silver-molybdenum Project in NW British Columbia; the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc.; the Langis and Hudson Bay silver Projects in Ontario; and the Atlin Goldfields Project in northwest BC. Brixton holds an option to acquire a 100% interest in the silver-focused Silvergruvan Project in Sweden. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707
Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Photos accompanying this announcement are available at:

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-1_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-2_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-3_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-4_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-5_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-6_06Oct2026-scaled.png

 And 6.45 m of 667 g/t Silver, Including 3.19 m of 1,339 g/t Silver In Hole 412

And 9.00 m of 222 g/t Silver, Including 0.50 m of 1,605 g/t Silver In Hole 442

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to report silver results from 28 holes at its wholly owned Langis Silver Project, located in the historic silver mining camp of Cobalt, Ontario, Canada. These results come from several different areas of the project that the Company is actively exploring. So far in 2026, the Company has completed 39,937.55 m across 182 drill holes. The Company has added a third drill rig to the Langis program, targeting 9,000 metres per month. This accelerated drilling rate is needed to meet our near-term objective of establishing a maiden Mineral Resource Estimate (“MRE”) at Langis.

Highlights

• In the Shaft 6 South East Area (S6-SE), hole LM-26-449 returned 23.50 m of 348 g/t silver from 203.00 m
  • Including 4.00 m of 1,975 g/t silver from 215.00 m
    • And including 2.00 m of 3,386 g/t silver from 215.50 m as native silver
• In the Shaft 6 West Area (S6-W), hole LM-26-412 returned 6.45 m of 667 g/t silver from 124.65 m
  • Including 3.19 m of 1,339 g/t silver from 127.31 m, and 1.00 m of 3,570 g/t silver from 128.40 m
• In the Shaft 6 East Area (S6-E), hole LM-26-433 returned 10.50 m of 85.7 g/t silver from 192.50 m
  • Including 2.35 m of 347 g/t silver from 196.25 m
• In the Shaft 6 Area (S6), hole LM-26-442 returned 9.00 m of 222 g/t silver from 119.00 m
  • Including 0.50 m of 1,605 g/t silver from 124.35 m, and 1.20 m of 666 g/t silver from 126.80 m

Chairman and CEO, Gary R. Thompson, stated, “Drilling at Langis continues to shine, delivering more multi-kilogram silver intercepts. Our high-density drilling strategy is showing results. These holes come from several different areas of the project as we are actively looking to expand known mineralization across the project.”

Figure 1. Langis Silver Project location map of drilling area and mineral claims.

Figure 2. Photograph of hole LM-26-449 at 215.73-216.00 m depth showing disseminated native silver and native silver veinlets.

Figure 3. Photograph of hole LM-26-449 at 215.73-216.00 m depth and LM-26-412 at 129.10 m depth showing native silver veins-veinlets and disseminated native silver.

Discussion

Shaft 6 South East (S6-SE)

New results from this recently discovered brownfield area (Table 1), with no mining works (see news release dated July 21, 2026), show mineralization extending to the south. Drilling to test the extension of this zone returned strong results in holes LM-26-421, LM-26-427 and LM-26-449, with hole LM-26-449 returning the main intercept of 23.50 m of 348.11 g/t silver from 203.00 m depth.

As observed in Figures 2 and 3, disseminated native silver accompanies the vein-hosted mineralization and native silver veinlets. Brixton interprets this as an upside to the traditional vein-focused exploration approach at Langis, as the disseminated silver appears to create broad shoulders of mineralization flanking the veins, which could significantly widen the mineralized envelopes.

Table 1. Selected assay intervals from drill holes in the Shaft 6 South East (S6-SE) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-419	140.00	142.00	2.00	54.80
LM-26-421	135.70	144.00	8.30	137.45
including	137.05	140.00	2.95	343.14
	150.45	150.95	0.50	140.00
	155.00	156.00	1.00	100.00
LM-26-427	179.00	185.00	6.00	95.55
including	182.00	182.50	0.50	987.00
LM-26-449	203.00	226.50	23.50	348.11
including	206.15	206.65	0.50	67.60
including	212.00	213.00	1.00	129.60
including	215.00	219.00	4.00	1,974.88
and including	215.50	217.50	2.00	3,386.25

No significant intercepts were returned from hole LM-26-425.
Note for all assay tables: All assay values are weighted averages. Reported intervals are drilling lengths, and the true widths of the mineralized intervals have not yet been determined. Reported intervals are length-weighted composites calculated at a 5 g/t Ag cut-off over contiguous samples, with limited internal dilution. A hole is reported as a significant intercept only where it contains a sub-interval exceeding 50 g/t Ag; otherwise, it is reported as no significant intercepts. Higher-grade “including” intervals reflect geological interpretation.

Shaft 6 East (S6-E)

Drilling in the Shaft 6 East (S6-E) area (Table 2) tested mineralization in this zone, with good results in holes LM-26-429 and LM-26-433; the latter returned 10.50 m of 85.74 g/t silver from 192.50 m depth. However, the Company has not yet established significant continuity of mineralization. While the mineralized intercepts warrant further exploration, the mineralization in S6-E is being intersected at greater depths, and the Company has therefore decided to move to shallower zones.

Table 2. Selected assay intervals from drill holes in the Shaft 6 East (S6-E) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-429	181.65	188.00	6.35	95.35
including	186.00	188.00	2.00	289.00
LM-26-431	227.70	228.25	0.55	240.00
LM-26-433	192.50	203.00	10.50	85.74
including	196.25	198.60	2.35	346.69
LM-26-441	210.00	217.20	7.20	11.55
including	214.50	215.00	0.50	61.40
	221.00	228.75	7.75	10.80
including	228.25	228.75	0.50	88.50
LM-26-443	206.50	207.50	1.00	43.75
including	207.00	207.50	0.50	77.70

No significant intercepts were returned from holes LM-26-437, LM-26-439 and LM-26-445.

Shaft 6 (S6)

In the Shaft 6 (S6) area (Table 3), drilling also continues to return good results around historic stopes, including holes LM-26-426, LM-26-428 and LM-26-442, with hole LM-26-442 returning the main intercept of 9.00 m of 221.91 g/t silver from 119.00 m depth.

Table 3. Selected assay intervals from drill holes in the Shaft 6 (S6) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-426	124.50	131.50	7.00	208.39
including	129.50	130.50	1.00	1,345.00
and including	130.00	130.50	0.50	2,200.00
LM-26-428	127.00	131.00	4.00	259.49
including	128.00	130.00	2.00	507.95
and including	129.00	129.50	0.50	1,090.00
	134.75	136.00	1.25	59.10
LM-26-435	132.00	137.00	5.00	41.91
including	132.00	133.00	1.00	102.00
LM-26-442	119.00	128.00	9.00	221.91
including	120.50	122.85	2.35	129.20
including	124.35	124.85	0.50	1,605.00
including	126.80	128.00	1.20	665.83
and including	126.80	127.50	0.70	1,055.00

No significant intercepts were returned from holes LM-26-430, LM-26-436, LM-26-438, LM-26-440, LM-26-444 and LM-26-446.

Shaft 6 West (S6-W)

Drilling in the Shaft 6 West (S6-W) area (Table 4) continues to confirm the good initial results reported in the news release dated September 2, 2026, with mineralization around the historic mine workings. Good results were returned in holes LM-26-412, LM-26-417, LM-26-420A and LM-26-424, with hole LM-26-412 returning the main intercept of 6.45 m of 666.95 g/t silver from 124.65 m depth.

Brixton is looking to potentially expand this mineralization at S6-W to demonstrate continuity, as the Company has been doing in the Shaft 6 South East (S6-SE) area.

Table 4. Selected assay intervals from drill holes in the Shaft 6 West (S6-W) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-412	124.65	131.10	6.45	666.95
including	127.31	130.50	3.19	1,339.39
and including	128.40	129.40	1.00	3,570.00
	135.10	145.42	10.32	102.64
including	137.50	138.00	0.50	584.00
including	141.50	143.00	1.50	441.67
LM-26-417	107.00	119.98	12.98	20.52
including	107.00	108.00	1.00	76.00
including	108.50	109.00	0.50	70.10
	122.00	129.21	7.21	137.53
including	122.00	123.00	1.00	427.00
including	126.00	128.21	2.21	239.60
	136.00	144.00	8.00	117.80
including	141.50	142.00	0.50	1,750.00
LM-26-420A	103.00	114.00	11.00	77.93
including	108.50	109.50	1.00	588.00
including	111.50	114.00	2.50	64.38
LM-26-424	121.50	136.25	14.75	46.48
including	123.50	125.00	1.50	368.33

No significant intercepts were returned from hole LM-26-422.

Figure 4. Plan Map of Langis showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to surface.

Shaded areas show where individual drill core samples from previous drilling returned ≥30 g/t Ag, projected to surface (Figures 4 & 6) or onto the section plane (Figure 5). They are a visual aid only. They are not a geological model, a mineral resource or a mineral reserve, and they do not imply continuity of mineralization between drill holes.

Figure 5. Long section A to A’ looking north (trace as in Figure 4), showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to the long-section plane.

Drill holes between 5,270,680 m N and 5,270,910 m N are projected onto a vertical west–east plane along 5,270,795 m N. Only the holes in this release are labelled and drawn with their lithology: Huronian conglomerate, Keewatin mafic volcanics and Nipissing diabase. Composites are plotted at the interval mid-point and coloured by silver grade. Shaded areas show samples ≥30 g/t Ag from previous drilling within the same window. No vertical exaggeration. Projection: points up to 115 m from the section line appear together, so intercepts that look close on the section may be separated in three dimensions. Composites and shading: same definitions and limitations as Figure 4. Reported intercepts are core lengths; true widths are not yet known.

Figure 6. Map showing drill results from the Langis Shaft 6 area, highlights from the 2026 campaign to date.

Table 5. Drill hole collar information for reported holes.

Hole ID	Pad ID	Easting (m)	Northing (m)	Elevation (m)	Azimuth	Dip	Depth (m)	Zone
LM-26-412	LM-2026-039	607210	5270820	212.0	300	-60	195.00	S6-W
LM-26-417	LM-2026-092	607230	5270820	212.9	305	-55	210.00	S6-W
LM-26-419	LM-2026-072	607550	5270728	216.9	85	-60	300.00	S6-SE
LM-26-420A	LM-2026-092	607230	5270820	212.9	295	-55	189.00	S6-W
LM-26-421	LM-2026-087	607451	5270726	217.0	90	-55	258.00	S6-SE
LM-26-422	LM-2026-093	607210	5270840	212.7	305	-50	189.00	S6-W
LM-26-424	LM-2026-093	607210	5270840	212.7	300	-55	186.00	S6-W
LM-26-425	LM-2026-085	607429	5270760	217.0	90	-55	288.00	S6-SE
LM-26-426	LM-2026-101	607401	5270805	216.6	355	-62	198.00	S6
LM-26-427	LM-2026-085	607429	5270760	217.0	90	-48	300.00	S6-SE
LM-26-428	LM-2026-101	607401	5270805	216.6	3	-63	195.00	S6
LM-26-429	LM-2026-097	607624	5270839	220.8	85	-70	249.00	S6-E
LM-26-430	LM-2026-102	607433	5270886	218.8	230	-72	177.00	S6
LM-26-431	LM-2026-097	607624	5270839	220.8	90	-65	252.00	S6-E
LM-26-433	LM-2026-096	607618	5270819	219.9	85	-70	276.00	S6-E
LM-26-435	LM-2026-102	607433	5270886	218.8	230	-59	180.00	S6
LM-26-436	LM-2026-102	607433	5270886	218.8	230	-55	210.00	S6
LM-26-437	LM-2026-096	607618	5270819	219.9	85	-65	276.00	S6-E
LM-26-438	LM-2026-103	607432	5270895	218.8	230	-66	84.00	S6
LM-26-439	LM-2026-098	607631	5270796	219.9	85	-70	300.00	S6-E
LM-26-440	LM-2026-103	607432	5270895	218.8	230	-70	121.50	S6
LM-26-441	LM-2026-099	607638	5270772	219.5	85	-70	300.00	S6-E
LM-26-442	LM-2026-103	607432	5270895	218.8	215	-73	177.00	S6
LM-26-443	LM-2026-096A	607613	5270809	220.0	85	-65	303.00	S6-E
LM-26-444	LM-2026-103	607432	5270895	218.8	230	-65	177.00	S6
LM-26-445	LM-2026-096A	607613	5270809	220.0	85	-70	298.00	S6-E
LM-26-446	LM-2026-103	607432	5270895	218.8	230	-59	192.00	S6
LM-26-449	LM-2026-094	607559	5270725	216.9	96	-58	276.00	S6-SE

About the Langis Project

An Exploration Target of 1.0 to 2.0 million tonnes grading 400 to 800 g/t silver has been conceptualized for the project. Note: The potential quantity and grade of the Exploration Target are conceptual. Insufficient exploration has been completed to define a mineral resource, and there is no certainty that further exploration will result in the target being delineated as a mineral resource.

The wholly owned Langis Silver Project, located approximately 500 km north of Toronto, Ontario, Canada, includes a former producing mine and benefits from excellent infrastructure, including all-season road access, power, rail connections, and a refiner. Silver mineralization occurs as native silver and in steeply to moderately dipping veins, veinlets, disseminations, rosettes, and fracture infill, often associated with minerals such as calcite, hematite, pyrite, cobaltite, chalcopyrite, niccolite, and gold. Mineralization is hosted across three principal rock types: Archean Keewatin volcanic and metasedimentary rocks, Proterozoic Coleman Member sedimentary rocks of the Huronian Supergroup, and Proterozoic Nipissing diabase. The geological deposit model for the area is a continental-rift extensional depositional environment. The Langis Mine produced 10.4 million ounces of silver intermittently between 1908 and 1989 at a head grade of 20 to 25 opt, with reported recoveries of 88% to 98%. Previous operators developed over 10 km of underground workings; however, shafts and openings have been capped and sealed. Historically, reported silver mines in the Cobalt Camp have collectively produced over 445 million ounces of silver. We also understand, through personal communication with mine workers in the camp, that ultra-high-grade native silver collector pieces did not make it through the mills, suggesting that the camp’s actual silver production is significantly higher than the reported numbers. The historic production figures referenced above are sourced from third-party records and personal communications, have not been verified by Brixton or by the Qualified Person, and should not be relied upon.

Quality Assurance & Quality Control

Quality assurance and quality control protocols for drill core sampling were developed by Brixton. Core samples were mostly taken at 2.0 m intervals. High-grade intervals were taken at 0.50 m to 1.00 m intervals. Blanks, duplicates (lab pulp), and certified reference materials were inserted at a combined rate of up to 15%. Core samples were cut in half, bagged, zip-tied, and sent directly to the ALS Minerals preparation facility in Sudbury, Ontario. ALS Minerals Laboratories is registered to ISO 9001:2015 and ISO 17025 accreditations for laboratory procedures. Samples were analyzed at ALS Laboratory Facilities in North Vancouver, British Columbia, for gold by fire assay with an atomic absorption finish. Ag, Pb, Cu, and Zn, as well as 48 additional elements, were analyzed using a four-acid digestion with an ICP-MS finish. Overlimit silver samples were analyzed using fire assay and gravimetric finish, and/or fire assay and gravimetric finish on concentrates. The certified reference materials were acquired from CDN Resource Laboratories Ltd. of Langley, British Columbia, and the standards inserted varied with the type and abundance of mineralization observed in the primary sample. Blank material used consisted of non-mineralized siliceous landscaping rock. A copy of the QAQC protocols is available on the Company’s website.

Corporate Update

On October 1, 2026, Eldorado Gold Corporation gave notice of termination to Brixton for its Earn-in Agreement for the Atlin Goldfields Project. The Atlin Goldfields Project is an exploration stage project with orogenic and intrusion related gold deposit type characteristics. Brixton holds the project 100% free and clear with low to no NSR’s. The Company intends to seek a farmout or sale of the Project. Several high-grade gold showings have seen limited work.

Qualified Person (QP)

Mr. Gary Thompson, P.Geo., is the Chairman and CEO and a senior geologist for the Company who is a Qualified Person as defined by National Instrument 43-101. Mr. Thompson has verified the referenced data and analytical results disclosed in this press release and has approved the technical information presented herein.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on advancing its mining projects. Brixton wholly owns five exploration projects: the Thorn copper-gold-silver-molybdenum Project in NW British Columbia; the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc.; the Langis and Hudson Bay silver Projects in Ontario; and the Atlin Goldfields Project in northwest BC. Brixton holds an option to acquire a 100% interest in the silver-focused Silvergruvan Project in Sweden. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707
Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Photos accompanying this announcement are available at:

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-1_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-2_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-3_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-4_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-5_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-6_06Oct2026-scaled.png

 And 6.45 m of 667 g/t Silver, Including 3.19 m of 1,339 g/t Silver In Hole 412

And 9.00 m of 222 g/t Silver, Including 0.50 m of 1,605 g/t Silver In Hole 442

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to report silver results from 28 holes at its wholly owned Langis Silver Project, located in the historic silver mining camp of Cobalt, Ontario, Canada. These results come from several different areas of the project that the Company is actively exploring. So far in 2026, the Company has completed 39,937.55 m across 182 drill holes. The Company has added a third drill rig to the Langis program, targeting 9,000 metres per month. This accelerated drilling rate is needed to meet our near-term objective of establishing a maiden Mineral Resource Estimate (“MRE”) at Langis.

Highlights

• In the Shaft 6 South East Area (S6-SE), hole LM-26-449 returned 23.50 m of 348 g/t silver from 203.00 m
  • Including 4.00 m of 1,975 g/t silver from 215.00 m
    • And including 2.00 m of 3,386 g/t silver from 215.50 m as native silver
• In the Shaft 6 West Area (S6-W), hole LM-26-412 returned 6.45 m of 667 g/t silver from 124.65 m
  • Including 3.19 m of 1,339 g/t silver from 127.31 m, and 1.00 m of 3,570 g/t silver from 128.40 m
• In the Shaft 6 East Area (S6-E), hole LM-26-433 returned 10.50 m of 85.7 g/t silver from 192.50 m
  • Including 2.35 m of 347 g/t silver from 196.25 m
• In the Shaft 6 Area (S6), hole LM-26-442 returned 9.00 m of 222 g/t silver from 119.00 m
  • Including 0.50 m of 1,605 g/t silver from 124.35 m, and 1.20 m of 666 g/t silver from 126.80 m

Chairman and CEO, Gary R. Thompson, stated, “Drilling at Langis continues to shine, delivering more multi-kilogram silver intercepts. Our high-density drilling strategy is showing results. These holes come from several different areas of the project as we are actively looking to expand known mineralization across the project.”

Figure 1. Langis Silver Project location map of drilling area and mineral claims.

Figure 2. Photograph of hole LM-26-449 at 215.73-216.00 m depth showing disseminated native silver and native silver veinlets.

Figure 3. Photograph of hole LM-26-449 at 215.73-216.00 m depth and LM-26-412 at 129.10 m depth showing native silver veins-veinlets and disseminated native silver.

Discussion

Shaft 6 South East (S6-SE)

New results from this recently discovered brownfield area (Table 1), with no mining works (see news release dated July 21, 2026), show mineralization extending to the south. Drilling to test the extension of this zone returned strong results in holes LM-26-421, LM-26-427 and LM-26-449, with hole LM-26-449 returning the main intercept of 23.50 m of 348.11 g/t silver from 203.00 m depth.

As observed in Figures 2 and 3, disseminated native silver accompanies the vein-hosted mineralization and native silver veinlets. Brixton interprets this as an upside to the traditional vein-focused exploration approach at Langis, as the disseminated silver appears to create broad shoulders of mineralization flanking the veins, which could significantly widen the mineralized envelopes.

Table 1. Selected assay intervals from drill holes in the Shaft 6 South East (S6-SE) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-419	140.00	142.00	2.00	54.80
LM-26-421	135.70	144.00	8.30	137.45
including	137.05	140.00	2.95	343.14
	150.45	150.95	0.50	140.00
	155.00	156.00	1.00	100.00
LM-26-427	179.00	185.00	6.00	95.55
including	182.00	182.50	0.50	987.00
LM-26-449	203.00	226.50	23.50	348.11
including	206.15	206.65	0.50	67.60
including	212.00	213.00	1.00	129.60
including	215.00	219.00	4.00	1,974.88
and including	215.50	217.50	2.00	3,386.25

No significant intercepts were returned from hole LM-26-425.
Note for all assay tables: All assay values are weighted averages. Reported intervals are drilling lengths, and the true widths of the mineralized intervals have not yet been determined. Reported intervals are length-weighted composites calculated at a 5 g/t Ag cut-off over contiguous samples, with limited internal dilution. A hole is reported as a significant intercept only where it contains a sub-interval exceeding 50 g/t Ag; otherwise, it is reported as no significant intercepts. Higher-grade “including” intervals reflect geological interpretation.

Shaft 6 East (S6-E)

Drilling in the Shaft 6 East (S6-E) area (Table 2) tested mineralization in this zone, with good results in holes LM-26-429 and LM-26-433; the latter returned 10.50 m of 85.74 g/t silver from 192.50 m depth. However, the Company has not yet established significant continuity of mineralization. While the mineralized intercepts warrant further exploration, the mineralization in S6-E is being intersected at greater depths, and the Company has therefore decided to move to shallower zones.

Table 2. Selected assay intervals from drill holes in the Shaft 6 East (S6-E) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-429	181.65	188.00	6.35	95.35
including	186.00	188.00	2.00	289.00
LM-26-431	227.70	228.25	0.55	240.00
LM-26-433	192.50	203.00	10.50	85.74
including	196.25	198.60	2.35	346.69
LM-26-441	210.00	217.20	7.20	11.55
including	214.50	215.00	0.50	61.40
	221.00	228.75	7.75	10.80
including	228.25	228.75	0.50	88.50
LM-26-443	206.50	207.50	1.00	43.75
including	207.00	207.50	0.50	77.70

No significant intercepts were returned from holes LM-26-437, LM-26-439 and LM-26-445.

Shaft 6 (S6)

In the Shaft 6 (S6) area (Table 3), drilling also continues to return good results around historic stopes, including holes LM-26-426, LM-26-428 and LM-26-442, with hole LM-26-442 returning the main intercept of 9.00 m of 221.91 g/t silver from 119.00 m depth.

Table 3. Selected assay intervals from drill holes in the Shaft 6 (S6) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-426	124.50	131.50	7.00	208.39
including	129.50	130.50	1.00	1,345.00
and including	130.00	130.50	0.50	2,200.00
LM-26-428	127.00	131.00	4.00	259.49
including	128.00	130.00	2.00	507.95
and including	129.00	129.50	0.50	1,090.00
	134.75	136.00	1.25	59.10
LM-26-435	132.00	137.00	5.00	41.91
including	132.00	133.00	1.00	102.00
LM-26-442	119.00	128.00	9.00	221.91
including	120.50	122.85	2.35	129.20
including	124.35	124.85	0.50	1,605.00
including	126.80	128.00	1.20	665.83
and including	126.80	127.50	0.70	1,055.00

No significant intercepts were returned from holes LM-26-430, LM-26-436, LM-26-438, LM-26-440, LM-26-444 and LM-26-446.

Shaft 6 West (S6-W)

Drilling in the Shaft 6 West (S6-W) area (Table 4) continues to confirm the good initial results reported in the news release dated September 2, 2026, with mineralization around the historic mine workings. Good results were returned in holes LM-26-412, LM-26-417, LM-26-420A and LM-26-424, with hole LM-26-412 returning the main intercept of 6.45 m of 666.95 g/t silver from 124.65 m depth.

Brixton is looking to potentially expand this mineralization at S6-W to demonstrate continuity, as the Company has been doing in the Shaft 6 South East (S6-SE) area.

Table 4. Selected assay intervals from drill holes in the Shaft 6 West (S6-W) zone.

Hole ID	From (m)	To (m)	Length (m)	Ag (g/t)
LM-26-412	124.65	131.10	6.45	666.95
including	127.31	130.50	3.19	1,339.39
and including	128.40	129.40	1.00	3,570.00
	135.10	145.42	10.32	102.64
including	137.50	138.00	0.50	584.00
including	141.50	143.00	1.50	441.67
LM-26-417	107.00	119.98	12.98	20.52
including	107.00	108.00	1.00	76.00
including	108.50	109.00	0.50	70.10
	122.00	129.21	7.21	137.53
including	122.00	123.00	1.00	427.00
including	126.00	128.21	2.21	239.60
	136.00	144.00	8.00	117.80
including	141.50	142.00	0.50	1,750.00
LM-26-420A	103.00	114.00	11.00	77.93
including	108.50	109.50	1.00	588.00
including	111.50	114.00	2.50	64.38
LM-26-424	121.50	136.25	14.75	46.48
including	123.50	125.00	1.50	368.33

No significant intercepts were returned from hole LM-26-422.

Figure 4. Plan Map of Langis showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to surface.

Shaded areas show where individual drill core samples from previous drilling returned ≥30 g/t Ag, projected to surface (Figures 4 & 6) or onto the section plane (Figure 5). They are a visual aid only. They are not a geological model, a mineral resource or a mineral reserve, and they do not imply continuity of mineralization between drill holes.

Figure 5. Long section A to A’ looking north (trace as in Figure 4), showing the drill hole collars and traces reported in this news release, along with 2026 drill collars, historic and Brixton assay results projected to the long-section plane.

Drill holes between 5,270,680 m N and 5,270,910 m N are projected onto a vertical west–east plane along 5,270,795 m N. Only the holes in this release are labelled and drawn with their lithology: Huronian conglomerate, Keewatin mafic volcanics and Nipissing diabase. Composites are plotted at the interval mid-point and coloured by silver grade. Shaded areas show samples ≥30 g/t Ag from previous drilling within the same window. No vertical exaggeration. Projection: points up to 115 m from the section line appear together, so intercepts that look close on the section may be separated in three dimensions. Composites and shading: same definitions and limitations as Figure 4. Reported intercepts are core lengths; true widths are not yet known.

Figure 6. Map showing drill results from the Langis Shaft 6 area, highlights from the 2026 campaign to date.

Table 5. Drill hole collar information for reported holes.

Hole ID	Pad ID	Easting (m)	Northing (m)	Elevation (m)	Azimuth	Dip	Depth (m)	Zone
LM-26-412	LM-2026-039	607210	5270820	212.0	300	-60	195.00	S6-W
LM-26-417	LM-2026-092	607230	5270820	212.9	305	-55	210.00	S6-W
LM-26-419	LM-2026-072	607550	5270728	216.9	85	-60	300.00	S6-SE
LM-26-420A	LM-2026-092	607230	5270820	212.9	295	-55	189.00	S6-W
LM-26-421	LM-2026-087	607451	5270726	217.0	90	-55	258.00	S6-SE
LM-26-422	LM-2026-093	607210	5270840	212.7	305	-50	189.00	S6-W
LM-26-424	LM-2026-093	607210	5270840	212.7	300	-55	186.00	S6-W
LM-26-425	LM-2026-085	607429	5270760	217.0	90	-55	288.00	S6-SE
LM-26-426	LM-2026-101	607401	5270805	216.6	355	-62	198.00	S6
LM-26-427	LM-2026-085	607429	5270760	217.0	90	-48	300.00	S6-SE
LM-26-428	LM-2026-101	607401	5270805	216.6	3	-63	195.00	S6
LM-26-429	LM-2026-097	607624	5270839	220.8	85	-70	249.00	S6-E
LM-26-430	LM-2026-102	607433	5270886	218.8	230	-72	177.00	S6
LM-26-431	LM-2026-097	607624	5270839	220.8	90	-65	252.00	S6-E
LM-26-433	LM-2026-096	607618	5270819	219.9	85	-70	276.00	S6-E
LM-26-435	LM-2026-102	607433	5270886	218.8	230	-59	180.00	S6
LM-26-436	LM-2026-102	607433	5270886	218.8	230	-55	210.00	S6
LM-26-437	LM-2026-096	607618	5270819	219.9	85	-65	276.00	S6-E
LM-26-438	LM-2026-103	607432	5270895	218.8	230	-66	84.00	S6
LM-26-439	LM-2026-098	607631	5270796	219.9	85	-70	300.00	S6-E
LM-26-440	LM-2026-103	607432	5270895	218.8	230	-70	121.50	S6
LM-26-441	LM-2026-099	607638	5270772	219.5	85	-70	300.00	S6-E
LM-26-442	LM-2026-103	607432	5270895	218.8	215	-73	177.00	S6
LM-26-443	LM-2026-096A	607613	5270809	220.0	85	-65	303.00	S6-E
LM-26-444	LM-2026-103	607432	5270895	218.8	230	-65	177.00	S6
LM-26-445	LM-2026-096A	607613	5270809	220.0	85	-70	298.00	S6-E
LM-26-446	LM-2026-103	607432	5270895	218.8	230	-59	192.00	S6
LM-26-449	LM-2026-094	607559	5270725	216.9	96	-58	276.00	S6-SE

About the Langis Project

An Exploration Target of 1.0 to 2.0 million tonnes grading 400 to 800 g/t silver has been conceptualized for the project. Note: The potential quantity and grade of the Exploration Target are conceptual. Insufficient exploration has been completed to define a mineral resource, and there is no certainty that further exploration will result in the target being delineated as a mineral resource.

The wholly owned Langis Silver Project, located approximately 500 km north of Toronto, Ontario, Canada, includes a former producing mine and benefits from excellent infrastructure, including all-season road access, power, rail connections, and a refiner. Silver mineralization occurs as native silver and in steeply to moderately dipping veins, veinlets, disseminations, rosettes, and fracture infill, often associated with minerals such as calcite, hematite, pyrite, cobaltite, chalcopyrite, niccolite, and gold. Mineralization is hosted across three principal rock types: Archean Keewatin volcanic and metasedimentary rocks, Proterozoic Coleman Member sedimentary rocks of the Huronian Supergroup, and Proterozoic Nipissing diabase. The geological deposit model for the area is a continental-rift extensional depositional environment. The Langis Mine produced 10.4 million ounces of silver intermittently between 1908 and 1989 at a head grade of 20 to 25 opt, with reported recoveries of 88% to 98%. Previous operators developed over 10 km of underground workings; however, shafts and openings have been capped and sealed. Historically, reported silver mines in the Cobalt Camp have collectively produced over 445 million ounces of silver. We also understand, through personal communication with mine workers in the camp, that ultra-high-grade native silver collector pieces did not make it through the mills, suggesting that the camp’s actual silver production is significantly higher than the reported numbers. The historic production figures referenced above are sourced from third-party records and personal communications, have not been verified by Brixton or by the Qualified Person, and should not be relied upon.

Quality Assurance & Quality Control

Quality assurance and quality control protocols for drill core sampling were developed by Brixton. Core samples were mostly taken at 2.0 m intervals. High-grade intervals were taken at 0.50 m to 1.00 m intervals. Blanks, duplicates (lab pulp), and certified reference materials were inserted at a combined rate of up to 15%. Core samples were cut in half, bagged, zip-tied, and sent directly to the ALS Minerals preparation facility in Sudbury, Ontario. ALS Minerals Laboratories is registered to ISO 9001:2015 and ISO 17025 accreditations for laboratory procedures. Samples were analyzed at ALS Laboratory Facilities in North Vancouver, British Columbia, for gold by fire assay with an atomic absorption finish. Ag, Pb, Cu, and Zn, as well as 48 additional elements, were analyzed using a four-acid digestion with an ICP-MS finish. Overlimit silver samples were analyzed using fire assay and gravimetric finish, and/or fire assay and gravimetric finish on concentrates. The certified reference materials were acquired from CDN Resource Laboratories Ltd. of Langley, British Columbia, and the standards inserted varied with the type and abundance of mineralization observed in the primary sample. Blank material used consisted of non-mineralized siliceous landscaping rock. A copy of the QAQC protocols is available on the Company’s website.

Corporate Update

On October 1, 2026, Eldorado Gold Corporation gave notice of termination to Brixton for its Earn-in Agreement for the Atlin Goldfields Project. The Atlin Goldfields Project is an exploration stage project with orogenic and intrusion related gold deposit type characteristics. Brixton holds the project 100% free and clear with low to no NSR’s. The Company intends to seek a farmout or sale of the Project. Several high-grade gold showings have seen limited work.

Qualified Person (QP)

Mr. Gary Thompson, P.Geo., is the Chairman and CEO and a senior geologist for the Company who is a Qualified Person as defined by National Instrument 43-101. Mr. Thompson has verified the referenced data and analytical results disclosed in this press release and has approved the technical information presented herein.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on advancing its mining projects. Brixton wholly owns five exploration projects: the Thorn copper-gold-silver-molybdenum Project in NW British Columbia; the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc.; the Langis and Hudson Bay silver Projects in Ontario; and the Atlin Goldfields Project in northwest BC. Brixton holds an option to acquire a 100% interest in the silver-focused Silvergruvan Project in Sweden. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707
Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Photos accompanying this announcement are available at:

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-1_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-2_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-3_06Oct2026-scaled.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-4_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-5_06Oct2026.png

https://brixtonmetals.com/wp-content/uploads/2026/10/Figure-6_06Oct2026-scaled.png